MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-12-2026
American Well Corporation EBITDA 2011-2026 | AMWL
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA American Well Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -71.3 M | -185 M | -661 M | -250 M | -163 M | -217 M | -86.9 M | -49.8 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -49.8 M | -661 M | -210 M |
Quarterly EBITDA American Well Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -19.9 M | -12.2 M | -22.6 M | - | -39.1 M | -44.2 M | -66.8 M | -135 M | -86.8 M | -390 M | - | -64.7 M | -62.7 M | -63.9 M | - | -46.1 M | -35.1 M | -36.2 M | - | -56.9 M | -83 M | -23.5 M | - | -20.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -12.2 M | -390 M | -68.9 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Health information services industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Cerner Corporation
CERN
|
1.43 B | - | - | $ 27.9 B |  USA |
 |
Accolade
ACCD
|
-38.6 M | - | 0.29 % | $ 206 M | USA |
 |
Computer Programs and Systems
CPSI
|
-40.7 M | - | 4.4 % | $ 133 M | USA |
 |
Covetrus
CVET
|
148 M | - | - | $ 2.94 B | USA |
 |
iCAD
ICAD
|
-6.03 M | - | - | $ 102 M | USA |
 |
Castlight Health, Inc.
CSLT
|
-5.95 M | - | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
140 M | - | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
187 M | - | - | $ 6.37 B | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
253 M | - | -10.39 % | $ 886 M | USA |
 |
MTBC
MTBC
|
23.3 M | - | -0.58 % | $ 51.7 M | USA |
 |
1Life Healthcare
ONEM
|
-197 M | - | - | $ 3.37 B | USA |
 |
HealthStream
HSTM
|
62.5 M | $ 22.03 | 1.52 % | $ 669 M | USA |
 |
Premier
PINC
|
119 M | - | - | $ 2.33 B | USA |
 |
R1 RCM
RCM
|
223 M | - | - | $ 3.81 B | USA |
 |
Evolent Health
EVH
|
70.8 M | $ 3.55 | 1.28 % | $ 333 M | USA |
 |
HealthEquity
HQY
|
271 M | $ 81.45 | 1.27 % | $ 6.97 B | USA |
 |
Change Healthcare
CHNG
|
691 M | - | - | $ 9.03 B | USA |
 |
Omnicell
OMCL
|
82.6 M | $ 41.51 | 1.73 % | $ 1.91 B | USA |
 |
GoodRx Holdings
GDRX
|
135 M | $ 2.19 | 5.8 % | $ 845 M | USA |
 |
Progyny
PGNY
|
19 M | $ 17.95 | 2.43 % | $ 1.54 B | USA |
 |
Health Catalyst
HCAT
|
-28.4 M | $ 1.94 | 12.79 % | $ 117 M | USA |
 |
Akerna Corp.
KERN
|
-6.57 M | - | - | $ 161 M | USA |
 |
Schrödinger
SDGR
|
-161 M | $ 13.17 | 5.32 % | $ 967 M | USA |
 |
Teladoc Health
TDOC
|
87.8 M | $ 5.2 | 1.76 % | $ 916 M | USA |
 |
So-Young International
SY
|
-579 M | $ 2.89 | 3.96 % | $ 229 M |  China |
 |
10x Genomics
TXG
|
-230 M | $ 22.46 | -0.73 % | $ 2.63 B | USA |
 |
SCWorx Corp.
WORX
|
-1.26 M | $ 0.14 | -19.22 % | $ 204 K | USA |
 |
NantHealth
NH
|
-35.3 M | - | -46.64 % | $ 10.4 M | USA |
 |
OptimizeRx Corporation
OPRX
|
-24 M | $ 7.94 | 8.47 % | $ 136 M | USA |
 |
NextGen Healthcare
NXGN
|
20.8 M | - | - | $ 1.6 B | USA |
 |
Veeva Systems
VEEV
|
435 M | $ 188.53 | 1.38 % | $ 30.3 B | USA |
 |
Phreesia
PHR
|
-107 M | $ 12.67 | 2.34 % | $ 691 M | USA |
 |
Zhongchao
ZCMD
|
-110 K | $ 1.69 | -1.98 % | $ 8.8 M | China |
 |
Signify Health
SGFY
|
63.3 M | - | -0.02 % | $ 7.21 B | USA |
 |
Streamline Health Solutions
STRM
|
-3.18 M | - | - | $ 21.4 M | USA |
 |
Tabula Rasa HealthCare
TRHC
|
-45.6 M | - | - | $ 255 M | USA |